Alemtuzumab in refractory Sézary syndrome
An. bras. dermatol
;
91(5): 642-644, Sept.-Oct. 2016. graf
Article
Dans Anglais
| LILACS
| ID: biblio-827761
ABSTRACT
Abstract Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Tumeurs cutanées
/
Syndrome de Sézary
/
Anticorps monoclonaux humanisés
/
Antinéoplasiques
Limites du sujet:
Adulte très âgé
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
An. bras. dermatol
Thème du journal:
Dermatologie
Année:
2016
Type:
Article
Pays d'affiliation:
Espagne
Institution/Pays d'affiliation:
Hospital Universitario Reina Sofía/ES
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS